Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
7/25/24 | AstraZeneca (AZN) | Imfinzi for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
7/25/24 | Chemomab Therapeutics (CMMB) | CM-101 for Primary Sclerosing Cholangitis (PSC) | Subscribers Only | Subscribers Only | Subscribers Only |
7/24/24 | Pfizer (PFE) | Giroctocogene Fitelparvovec for Hemophilia A | Subscribers Only | Subscribers Only | Subscribers Only |
7/23/24 | AstraZeneca (AZN) | Imfinzi for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
7/23/24 | Bausch Health (BHC) | Mytesi for Gastroenterologic Disorders | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
01/01/25 - 04/30/24 | Subscribers Only | Subscribers Only | Progress Update - Product Launch |
01/01/25 - 06/30/24 | Subscribers Only | Subscribers Only | Regulatory - MAA Submission (Europe) |
07/27/24 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (U.S.) |
07/28/24 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
07/28/24 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |